Fundraising Fox
/Companies
Sign in

Indapta Therapeutics

Houston, US · Delaware corporation · 3 known investors

Find your way into Indapta Therapeutics

Sign up to see every warm intro you have to Indapta Therapeutics

  • Paths you didn't know you had: your email and LinkedIn already hold routes to the Indapta Therapeutics team. We find them for you
  • 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
  • Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Sign up with GoogleAlready have an account? Log in

Indapta Therapeutics develops an off-the-shelf, allogeneic FcRγ-deficient natural killer (g-NK) cell therapy derived from healthy donors to treat cancer and autoimmune diseases. Its lead candidate IDP-023 is being tested in clinical trials for indications such as multiple myeloma, non-Hodgkin's lymphoma, and progressive multiple sclerosis.

BiotechHealthtech

Founders & leadership

GDGuy DiPierro
Guy DiPierroChief Operating Officer and FounderGuy DiPierro is Chief Operating Officer and co-founder of Indapta Therapeutics, which develops allogeneic natural killer cell therapy for cancer and autoimmune diseases. He has over 16 years of experience in specialty pharmaceuticals, previously served as Executive Vice President and General Counsel at AMGI Capital, and worked as an attorney in corporate M&A and technology licensing at Sidley Austin and Hogan and Hartson.
SK
Sungjin KimScientific Founder
JS
John SunwooScientific Founder
MWMark W. Frohlich
Mark W. FrohlichChief Executive Officer
SM
Stefanie Mandl-CashmanActing Chief Scientific Officer

Board

LH
Lori HuBoard directorManaging Director at Vertex Ventures HC
FPFabio Pucci
Fabio PucciMember Board Of Directors2022–2026Partner at Arkin Capital
LSLaura Stoppel
Laura StoppelBoard directorPartner at RA Capital
RMRonald Martell
Ronald MartellCo-Founder, Executive ChairmanStrategic Advisor, Founder at Encellin

Investors · 3

RA Capital✓ confirmed by Indapta TherapeuticsBoston

How we know: the company's own site · funding news · press coverage · Not right? Tell us

Vertex Ventures HC✓ confirmed by Indapta TherapeuticsSingapore · $500K – $10M

How we know: the company's own site · a partner's Signal profile · funding news · press coverage · Not right? Tell us

Reported raises · per SEC filings

Form D private placements

$84.4M disclosed across 2 of 3 rounds · 2022–2025

▶$50.8MraisedOct 2025 · 46 investors · Other Technology
Rule 506(b)
Officers, directors & promoters on the filing
  • Lori HuDirector
  • Fabio PucciDirector
  • Ronald MartellDirector
  • Mark FrohlichExecutive Officer, Director
Offering amount
$51.6M
Amount sold
$50.8M
First sale
Sep 2025
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$33.6MraisedFeb 2022 · 37 investors · Other Technology
Rule 506(b)
Officers, directors & promoters on the filing
  • Mark FrohlichExecutive Officer, Director
  • Ronald MartellDirector
  • Fabio PucciDirector
  • Laura StoppelDirector
  • Guy DiPierroExecutive Officer
  • Lori HuDirector
Offering amount
$67.1M
Amount sold
$33.6M
Sales commissions
$2.4M
First sale
Jan 2022
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Founder mafia

2 people who came through Indapta Therapeutics went on to found or lead other companies.

Ronald MartellChairman of the Board and Co-FounderFounded Encellin +3Guy DiPierroChief Operating Officer & Co-FounderFounded Chrono Therapeutics

Related companies · 2

BioworldBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.
Eli LillyEli Lilly discovers, develops, manufactures, and markets human pharmaceutical products across cardiometabolic, oncology, immunology, and neuroscience therapeutic areas, selling to healthcare providers and patients in approximately 90 countries through wholesalers, direct sales representatives, and digital platforms.

Companies working in the same space as Indapta Therapeutics.

In the news

Indapta Therapeutics Raises $22.5M in Fundingfinsmes.com · Dec 2024

Frequently asked questions

What does Indapta Therapeutics do?
Indapta Therapeutics develops an off-the-shelf, allogeneic FcRγ-deficient natural killer (g-NK) cell therapy derived from healthy donors to treat cancer and autoimmune diseases. Its lead candidate IDP-023 is being tested in clinical trials for indications such as multiple myeloma, non-Hodgkin's lymphoma, and progressive multiple sclerosis.
Who founded Indapta Therapeutics?
Indapta Therapeutics was founded by Guy DiPierro, Sungjin Kim, John Sunwoo.
Who are Indapta Therapeutics's investors?
Indapta Therapeutics's investors include Leaps by Bayer, RA Capital, Vertex Ventures HC.
How much funding has Indapta Therapeutics raised?
Indapta Therapeutics has disclosed $84.4M raised across 2 of its 3 known rounds.
Where is Indapta Therapeutics headquartered?
Indapta Therapeutics is headquartered in Houston, US.